Skip to main content
SpringerLink
Log in

Enhancement of dissolution and bioavailability of ezetimibe by amorphous solid dispersion nanoparticles fabricated using supercritical antisolvent process

  • Original Article
  • Published:
Journal of Pharmaceutical Investigation Aims and scope Submit manuscript

Abstract

The purpose of the present study was to fabricate ezetimibe-hydroxypropyl cellulose (HPC) solid dispersion nanoparticles with enhanced dissolution and oral bioavailability using the supercritical antisolvent (SAS) process. We investigated the influence of SAS process parameters (pressure, temperature, and solute concentration) on the formation of ezetimibe-HPC solid dispersion particles. Physico-chemical properties of solid dispersion nanoparticles were characterized by scanning electron microscopy, differential scanning calorimeter, powder X-ray diffraction, a particle size analyzer, and measurements of the specific surface area. The mean particle size of ezetimibe-HPC solid dispersions could be controlled by the solute concentration. Physico-chemical analysis demonstrated that ezetimibe is amorphous in all solid dispersions. The dissolution rate of the solid dispersion nanoparticles was inversely proportional to the mean particle size. Ezetimibe administered in the form of 150.6-nm HPC solid dispersion nanoparticles demonstrated rapid dissolution of up to 95 % of the total amount within 10 min, as well as higher oral bioavailability than the drug introduced in the physical mixture. We also observed 3.2- and 2.0-fold increases in Cmax and AUC0→24 h values, respectively, for ezetimibe administered in the nanoparticle form compared to the drug within the physical mixture. Therefore, these results demonstrated that dissolution and oral absorption of ezetimibe can be enhanced by formulating it in the form of amorphous HPC solid dispersion nanoparticles manufactured using the SAS process.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  • Baek IH, Kim MS (2012) Improved supersaturation and oral absorption of dutasteride by amorphous solid dispersions. Chem Pharm Bull 60:1468–1473

    Article  Google Scholar 

  • Bakhbakhi Y, Charpentier PA, Rohani S (2006) Experimental study of the GAS process for producing microparticles of beclomethasone-17,21-dipropionate suitable for pulmonary delivery. Int J Pharm 309:71–80

    Article  CAS  PubMed  Google Scholar 

  • Bali V, Ali M, Ali J (2010) Study of surfactant combinations and development of a novel nanoemulsion for minimising variations in bioavailability of ezetimibe. Colloid Surf B 76:410–420

    Article  CAS  Google Scholar 

  • Bali V, Ali M, Ali J (2011) Nanocarrier for the enhanced bioavailability of a cardiovascular agent: in vitro, pharmacodynamic, pharmacokinetic and stability assessment. Int J Pharm 403:46–56

    Article  CAS  PubMed  Google Scholar 

  • Bandyopadhyay S, Katare OP, Singh B (2012) Optimized self nano-emulsifying systems of ezetimibe with enhanced bioavailability potential using long chain and medium chain triglycerides. Colloid Surf B 100:50–61

    Article  CAS  Google Scholar 

  • Cho Y, Ha ES, Baek IH, Kim MS, Cho CW, Hwang SJ (2015) Enhanced supersaturation and oral absorption of sirolimus using an amorphous solid dispersion based on Eudragit® E. Molecules 20:9496–9509

    Article  CAS  PubMed  Google Scholar 

  • Dixit RP, Nagarsenker MS (2008) Self-nanoemulsifying granules of ezetimibe: design, optimization and evaluation. Euro J Pharm Sci 35:183–192

    Article  CAS  Google Scholar 

  • Esfandiari N (2015) Production of micro and nano particles of pharmaceutical by supercritical carbon dioxide. J Supercrit Fluids 100:129–141

    Article  CAS  Google Scholar 

  • Friedman HS, Rajagopalan S, Barnes JP, Roseman H (2011) Combination therapy with ezetimibe/simvastatin versus statin monotherapy for low-density lipoprotein cholesterol reduction and goal attainment in a real-world clinical setting. Clin Ther 33:212–224

    Article  CAS  PubMed  Google Scholar 

  • Gao P, Shi Y (2012) Characterization of supersaturatable formulations for improved absorption of poorly soluble drugs. AAPS J 14:703–713

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Gulsun T, Gursoy RN, Oner L (2011) Design and characterization of nanocrystal formulations containing ezetimibe. Chem Pharm Bull 59:41–45

    Article  CAS  PubMed  Google Scholar 

  • Ha ES, Baek IH, Cho W, Hwang SJ, Kim MS (2014a) Preparation and evaluation of solid dispersion of atorvastatin calcium with Soluplus® by spray drying technique. Chem Pharm Bull 62:545–551

    Article  CAS  PubMed  Google Scholar 

  • Ha ES, Choo GH, Baek IH, Kim MS (2014b) Formulation, characterization, and in vivo evaluation of celecoxib-PVP solid dispersion nanoparticles using supercritical antisolvent process. Molecules 19:20325–20339

    Article  CAS  PubMed  Google Scholar 

  • Juppo AM, Boissier C, Khoo C (2003) Evaluation of solid dispersion particles prepared with SEDS. Int J Pharm 250:385–401

    Article  CAS  PubMed  Google Scholar 

  • Khan KA, Rhodes CT (1972) Effect of compaction pressure on the dissolution efficiency of some direct compression systems. Pharm Acta Helv 47:594–607

    CAS  PubMed  Google Scholar 

  • Kim MS (2013) Influence of hydrophilic additives on the supersaturation and bioavailability of dutasteride-loaded hydroxypropyl-β-cyclodextrin nanostructures. Int J Nanomedicine 8:2029–2039

    Article  PubMed Central  PubMed  Google Scholar 

  • Kim MS, Baek IH (2014) Fabrication and evaluation of valsartan polymer surfactant composite nanoparticles using supercritical antisolvent process. Int J Nanomedicine 9:5167–5176

    Article  PubMed Central  PubMed  Google Scholar 

  • Kim MS, Lee S, Park JS, Woo JS, Hwang SJ (2007) Micronization of cilostazol using supercritical antisolvent (SAS) process: effect of process parameters. Powder Technol 177:64–70

    Article  CAS  Google Scholar 

  • Kim MS, Jin SJ, Kim JS, Park HJ, Song HS, Neubert RH, Hwang SJ (2008) Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Euro J Pharm Biopharm 69:454–465

    Article  CAS  Google Scholar 

  • Kim MS, Kim JS, Park HJ, Cho WK, Cha KH, Hwang SJ (2011) Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process. Int J Nanomedicine 6:2997–3009

    PubMed Central  CAS  PubMed  Google Scholar 

  • Kim MS, Song HS, Park HJ, Hwang SJ (2012) Effect of solvent type on the nanoparticle formation of atorvastatin calcium by the supercritical antisolvent process. Chem Pharm Bull 60:543–547

    Article  CAS  PubMed  Google Scholar 

  • Kim MS, Kim JS, Cho W, Cha KH, Park HJ, Park J, Hwang SJ (2013) Supersaturatable formulations for the enhanced oral absorption of sirolimus. Int J Pharm 445:108–116

    Article  CAS  PubMed  Google Scholar 

  • Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB (2005) Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 44:467–494

    Article  CAS  PubMed  Google Scholar 

  • Lee JY, Kang WS, Piao J, Yoon IS, Kim DD, Cho HJ (2015) Soluplus®/TPGS-based solid dispersions prepared by hot-melt extrusion equipped with twin-screw systems for enhancing oral bioavailability of valsartan. Drug Des Dev Ther 9:2745–2756

    Google Scholar 

  • Oswald S, Scheuch E, Cascorbi I, Siegmund W (2006) A LC–MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. J Chromatogr B 830:143–150

    Article  CAS  Google Scholar 

  • Patel R, Bhimani D, Patel J, Patel D (2008) Solid-state characterization and dissolution properties of ezetimibe–cyclodextrins inclusion complexes. J Incl Phenom Macrocycl Chem 60:241–251

    Article  CAS  Google Scholar 

  • Paudel A, Worku ZA, Meeus J, Guns S, Van den Mooter G (2013) Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: formulation and process considerations. Int J Pharm 453:253–284

    Article  CAS  PubMed  Google Scholar 

  • Rashid R, Kim DW, Din FU, Mustapha O, Yousaf AM, Park JH, Kim JO, Yong CS, Choi HG (2015) Effect of hydroxypropylcellulose and Tween 80 on physicochemical properties and bioavailability of ezetimibe-loaded solid dispersion. Carbohydr Polym 130:26–31

    Article  CAS  PubMed  Google Scholar 

  • Reverchon E, Marco ID, Porta GD (2002) Tailoring of nano- and micro-particles of some superconductor precursors by supercritical antisolvent precipitation. J Supercrit Fluids 23:81–87

    Article  CAS  Google Scholar 

  • Sancheti PP, Karekar P, Vyas VM, Shah M, Pore YV (2009) Preparation and physicochemical characterization of surfactant based solid dispersions of ezetimibe. Pharmazie 64:227–231

    CAS  PubMed  Google Scholar 

  • Secuianu C, Feroiu V, Geanǎ D (2008) Phase behavior for carbon dioxide + ethanol system: experimental measurements and modeling with a cubic equation of state. J Supercrit Fluids 47:109–116

    Article  CAS  Google Scholar 

  • Taupitz T, Dressman JB, Klein S (2013) New formulation approaches to improve solubility and drug release from fixed dose combinations: case examples pioglitazone/glimepiride and ezetimibe/simvastatin. Euro J Pharm Biopharm 84:208–218

    Article  CAS  Google Scholar 

  • Yasuji T, Takeuchi H, Kawashima Y (2008) Particle design of poorly water-soluble drug substances using supercritical fluid technologies. Adv Drug Deliv Rev 60:388–398

    Article  CAS  PubMed  Google Scholar 

  • Yin X, Daintree LS, Ding S, Ledger DM, Wang B, Zhao W, Qi J, Wu W (2015) Itraconazole solid dispersion prepared by a supercritical fluid technique: preparation, in vitro characterization, and bioavailability in beagle dogs. Drug Des Dev Ther 9:2801–2810

    Google Scholar 

Download references

Acknowledgments

All authors (E-S Ha, J-S Kim, I Baek, S-J Hwang, and M-S Kim) declare that they have no conflict of interest. This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (NRF-2014R1A1A1006492).

Author information

Author notes

    Authors and Affiliations

    1. College of Pharmacy, Pusan National University, 2, Busandaehak-ro 63beon-gil, Geumjeong-gu, Busan, 609-735, Republic of Korea

      Eun-Sol Ha & Min-Soo Kim

    2. Dong-A ST Co. Ltd., Giheung-gu, Yongin, Gyeonggi, 446-905, Republic of Korea

      Jeong-Soo Kim

    3. College of Pharmacy, Kyungsung University, Daeyeon-dong, Nam-gu, Busan, 608-736, Republic of Korea

      In-hwan Baek

    4. Yonsei Institute of Pharmaceutical Sciences and College of Pharmacy, Yonsei University, 162-1 Songdo-dong, Yeonsu-gu, Incheon, 406-840, Republic of Korea

      Sung-Joo Hwang

    Authors
    1. Eun-Sol Ha
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Jeong-Soo Kim
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. In-hwan Baek
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Sung-Joo Hwang
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Min-Soo Kim
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Min-Soo Kim.

    Additional information

    Eun-Sol Ha and Jeong-Soo Kim have equal contribution in this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Ha, ES., Kim, JS., Baek, Ih. et al. Enhancement of dissolution and bioavailability of ezetimibe by amorphous solid dispersion nanoparticles fabricated using supercritical antisolvent process. Journal of Pharmaceutical Investigation 45, 641–649 (2015). https://doi.org/10.1007/s40005-015-0218-8

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40005-015-0218-8

    Keywords

    Search

    Navigation